Literature DB >> 27446476

Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications.

Xuyu Yang1, Xiaoling Zhou2, Paul Tone3, Marian E Durkin4, Nicholas C Popescu4.   

Abstract

Human hepatocellular carcinoma (HCC) is one of the most common types of cancer and has a very poor prognosis; thus, the development of effective therapies for the treatment of advanced HCC is of high clinical priority. In the present study, the anti-oncogenic effect of combined knockdown of c-Myc expression and ectopic restoration of deleted in liver cancer 1 (DLC1) expression was investigated in human liver cancer cells. Expression of c-Myc in human HCC cells was knocked down by stable transfection with a Myc-specific short hairpin (sh) RNA vector. DLC1 expression in Huh7 cells was restored by adenovirus transduction, and the effects of DLC1 expression and c-Myc knockdown on Ras homolog gene family, member A (RhoA) levels, cell proliferation, soft agar colony formation and cell invasion were measured. Downregulation of c-Myc or re-expression of DLC1 led to a marked reduction in RhoA levels, which was associated with decreases in cell proliferation, soft agar colony formation and invasiveness; this inhibitory effect was augmented with a combination of DLC1 transduction and c-Myc suppression. To determine whether liver cell-specific delivery of DLC1 was able to enhance the inhibitory effect of c-Myc knockdown on tumor growth in vivo, DLC1 vector DNA complexed with galactosylated polyethylene glycol-linear polyethyleneimine was administered by tail vein injection to mice bearing subcutaneous xenografts of Huh7 cells transfected with shMyc or control shRNA. A cooperative inhibitory effect of DLC1 expression and c-Myc knockdown on the growth of Huh7-derived tumors was observed, suggesting that targeted liver cell delivery of DLC1 and c-Myc shRNA may serve as a possible gene therapy modality for the treatment of human HCC.

Entities:  

Keywords:  Ras homolog gene family guanosine triphosphatase; c-Myc; deleted in liver cancer 1; hepatocellular carcinoma; tumorigenesis

Year:  2016        PMID: 27446476      PMCID: PMC4950702          DOI: 10.3892/ol.2016.4781

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

Review 1.  Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST.

Authors:  Maria Reig; Anna Darnell; Alejandro Forner; Jordi Rimola; Carmen Ayuso; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2014-11-04       Impact factor: 6.115

2.  Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis.

Authors:  Szu-Wei Lee; Chien-Feng Li; Chia-Hsin Chan; Jing Wang; Wei-Lei Yang; Ching-Yuan Wu; Juan Wu; Keiichi I Nakayama; Hong-Yo Kang; Hsuan-Ying Huang; Mien-Chie Hung; Pier Paolo Pandolfi; Hui-Kuan Lin
Journal:  Nat Cell Biol       Date:  2010-04-11       Impact factor: 28.824

3.  Two human c-onc genes are located on the long arm of chromosome 8.

Authors:  B G Neel; S C Jhanwar; R S Chaganti; W S Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

Review 4.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

5.  Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.

Authors:  Hiroto Katoh; Hidenori Ojima; Akiko Kokubu; Shigeru Saito; Tadashi Kondo; Tomoo Kosuge; Fumie Hosoda; Issei Imoto; Johji Inazawa; Setsuo Hirohashi; Tatsuhiro Shibata
Journal:  Gastroenterology       Date:  2007-11       Impact factor: 22.682

6.  Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.

Authors:  Xiaolan Qian; Guorong Li; Holly K Asmussen; Laura Asnaghi; William C Vass; Richard Braverman; Kenneth M Yamada; Nicholas C Popescu; Alex G Papageorge; Douglas R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

Review 7.  Identification of drivers from cancer genome diversity in hepatocellular carcinoma.

Authors:  Atsushi Takai; Hien T Dang; Xin W Wang
Journal:  Int J Mol Sci       Date:  2014-06-20       Impact factor: 5.923

8.  Hepatocellular carcinoma: natural history, current management, and emerging tools.

Authors:  Christopher L Tinkle; Daphne Haas-Kogan
Journal:  Biologics       Date:  2012-07-17

9.  Developmental context determines latency of MYC-induced tumorigenesis.

Authors:  Shelly Beer; Anders Zetterberg; Rebecca A Ihrie; Ryan A McTaggart; Qiwei Yang; Nicole Bradon; Constadina Arvanitis; Laura D Attardi; Sandy Feng; Boris Ruebner; Robert D Cardiff; Dean W Felsher
Journal:  PLoS Biol       Date:  2004-09-28       Impact factor: 8.029

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  2 in total

Review 1.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

2.  ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes.

Authors:  Haaglim Cho; JungIn Um; Ji-Hyung Lee; Woong-Hee Kim; Wan Seok Kang; So Hun Kim; Hyung-Ho Ha; Yong-Chul Kim; Young-Keun Ahn; Da-Woon Jung; Darren R Williams
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.